Clinical features of taxane neuropathy

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Taxanes (paclitaxel, docetaxel) are crucial chemotherapy agents.
• Sensory neuropathy is a significant dose-limiting toxicity associated with taxane use.
• Understanding the mechanisms and clinical factors influencing taxane-induced neuropathy is vital for patient care.

Observation:

• Taxane neuropathy stems from interactions with neuronal microtubules and cytoskeletal components.
• Toxicity varies based on disease type, taxane class, dosage, schedule, patient demographics, and combination therapies (especially with platinum agents).
• Clinical manifestations of taxane neuropathy are diverse and can occur during treatment.

Findings:

• The primary method to prevent long-term sensory neuropathy is to discontinue the causative taxane agent.
• Current treatments offer minimal improvement for established taxane-induced neuropathy.
• This review examines clinical factors influencing the therapeutic window and susceptibility to taxane neurotoxicity.

Implications:

• Identifying factors that predict neuropathy risk can optimize taxane therapy.
• Improved understanding may lead to strategies for neuroprotection or dose modification.
• Managing taxane-induced neuropathy is essential for maintaining treatment adherence and quality of life in cancer patients.